Please enable Javascript
Katy Marshall
Katy Marshall
Articles by Katy Marshall
Fluoropyrimidine, Bevacizumab Plus Oxaliplatin for Older Patients With Unresectable Metastatic Colorectal Cancer
Katy Marshall
Colorectal Cancer
|
September 4, 2024
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
Read More
Evaluating the Incidence, Survival Outcomes of Gastrointestinal Stromal Tumors
Katy Marshall
GIST
|
August 28, 2024
Researchers specifically used data from the SEER-22 and SEER-17 registries.
Read More
Updated Guidelines for the Management of Locally Advanced Rectal Cancer
Katy Marshall
Colorectal Cancer
|
August 21, 2024
The systematic review included data from 12 randomized controlled trials, 2 systematic reviews, and 1 nonrandomized study.
Read More
Evaluating the Molecular, Clinicopathologic Effects of GNAS Variants in Solid Tumors
Katy Marshall
GI Cancer
|
August 16, 2024
GNAS-mutated tumors displayed C-to-T mutation-high, aneuploidy-low molecular profile.
Read More
FDA Accepts Supplemental New Drug Application for Cabozantinib in GEP-NETs
Katy Marshall
GEP-NETs
|
August 14, 2024
Cabozantinib can be used for patients with pNETs or epNETs.
Read More
Potential Benefits of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Katy Marshall
Colorectal Cancer
|
August 13, 2024
Investigators calculated the C-for-benefit to evaluate evidence for HTE.
Read More
Evaluating Chemotherapy-Induced Peripheral Neuropathy in Gastroesophageal Cancer
Katy Marshall
Gastroesophageal Cancer
|
August 7, 2024
Researchers noted that CIPN was negatively connected to HRQOL across all therapy groups.
Read More
Benefits of MRI Versus Dual-Energy CT in Local-Regional Staging for Patients With Gastric Cancer
Katy Marshall
Gastric Cancer
|
August 2, 2024
Currently, there is little research on the comparative accuracy of mpMRI versus DECT.
Read More
Best Supportive Care Versus Immunotherapy for Patients With Unresectable HCC
Katy Marshall
Unresectable HCC
|
August 1, 2024
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
Read More
Comparing Chemotherapy Options for Patients With Esophageal Squamous Cell Carcinoma
Katy Marshall
Gastroesophageal Cancer
|
July 30, 2024
The study compared neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy.
Read More
Potential of Interpretable AI to Determine Treatment With Imatinib for GISTs
Katy Marshall
GIST
|
July 24, 2024
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
Read More
FIGHT-202: Analyzing the Effects of Pemigatinib in Patients With Cholangiocarcinoma
Katy Marshall
Bile Duct Cancer
|
July 22, 2024
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
Read More
Stiripentol May Increase Chemotherapy Efficacy in Gastric Cancer
Katy Marshall
Gastric Cancer
|
July 18, 2024
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Read More
Analyzing Atezolizumab, Bevacizumab as a First-Line Treatment for Patients With HCC
Katy Marshall
Unresectable HCC
|
July 18, 2024
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
Read More
Patient-Reported Outcomes Following Tremelimumab Plus Durvalumab in Unresectable HCC
Katy Marshall
Unresectable HCC
|
July 12, 2024
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
Read More
Analyzing the Effects of Dendritic Cell-Based Immunotherapy on Resected Pancreatic Cancer
Katy Marshall
Pancreatic Cancer
|
July 11, 2024
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
Read More
Evaluating Bexarotene as a Targeted Therapy for SEZ6L2 in Colon Cancer
Katy Marshall
Colorectal Cancer
|
July 10, 2024
The potential uses of bexarotene, a retinoid, for patients with colon cancer have not been adequately explored.
Read More
Determining Prognosis for Patients With Metastatic Grade 1 GEP-NETs
Katy Marshall
GEP-NETs
|
July 4, 2024
While GEP-NETs are often torpid, the incidence of patients with GEP-NETs has increased over the last few years.
Read More
Real-World Analysis of Gemcitabine Plus Cisplatin, Durvalumab as a First-Line Treatment in BTC
Katy Marshall
Bile Duct Cancer
|
July 3, 2024
The study's primary end point was overall survival.
Read More
Investigating the Potential of Targeted Therapies for Patients With Colorectal Cancer
Katy Marshall
Colorectal Cancer
|
July 2, 2024
The effects of targeted therapies are deterred by a rapid emergence of resistance.
Read More
Load More